Marta Domenech, Carles Fabregat-Franco, Carlos Mesia, et al.
The study authors conclude that adding 6 cycles of temozolomide after the first 6 adjuvant cycles confers no additional benefit in overall survival. Nearly 50% of the patients included in GEINO 1401 - previously treated with temozolomide 6 cycles without progressing - were long-term survivor patients. Clinical trial information: NCT02209948
Eudocia Quant Lee, Lorenzo Trippa, Geoffrey Fell, et al.
The study authors conclude that Abemaciclib was well-tolerated and prolonged progression-free survival. However, there is no evidence of an overall survival improvement compared to standard radiochemotherapy. Clinical trial information: NCT02977780
Manmeet Singh Ahluwalia, Yasmeen Rauf, Hong Li, et al.
The study authors conclude that overall rates of progression-free and overall survival appear similar for nivolumab with either standard or low-dose bevacizumab compared to historical benchmarks of bevacizumab monotherapy. They further conclude that Nivolumab with standard bevacizumab may benefit older but not younger patients. Clinical trial information: NCT03452579
Yasaman Damestani, Minesh P. Mehta, Howard Colman, et al.
The study authors conclude that XPORT-GBM-029 trial is probably the first large, prospective, longitudinal study in patients with glioblastoma multiforme employing digital markers. This study may provide useful information regarding the utility of wearable and mobile devices for measuring functional outcomes in clinical trials. Clinical trial information: NCT04421378
Patrick Y. Wen, Michael Castro, Drew Watson, et al.
The study authors conclude that the Singula TRI Score provides a continuous measure scaled from 0 (low benefit) to 100 (high benefit) for alternative glioblastoma multiforme therapeutic options. Singula was strongly predictive of overall and disease-free survival and provided predictive value beyond physician-prescribed treatments, patient age, and gender.
Hui-Kuo George Shu, Eric Albert Mellon, Lawrence Kleinberg, et al.
The study authors conclude that dose-escalated RT to 75 Gy guided by sMRI appears feasible and safe for patients with newly-diagnosed glioblastoma multiforme. Overall survival outcome is also quite promising and warrants additional testing. Clinical trial information: NCT03137888
David C Qian, Joseph A. Marascio, Stewart G. Neill, et al.
The study authors conclude that this study successfully identified an expression signature of five genes that stratified outcomes among lower-grade glioma patients who received adjuvant radiotherapy, with two rounds of validation leveraging independent genomics databases. The authors further note, that expression levels of the highlighted genes were associated with survival only among patients with radiotherapy, but not among those without radiotherapy. This suggests that the expression of these genes may be predictive of radiation treatment response.
The study authors conclude that their work illustrates the immune landscape of brain metastases from NSCLC, and suggests that the tumor immune microenvironment in brain metastases compared with primary lung tumors is further immunosuppressed. This may help guide immunotherapeutic strategies for NSCLC brain metastases.
Gaia Griguolo, Anna Tosi, Valentina Guarneri, et al.
The study authors show that In breast cancer (BC) brain metastases (BM), stromal TIM3+ immune infiltrate differs according to BC subtype. They further show, that M2 macrophage polarization is consistently associated with worse overall survival across all BC subtypes and might represent a potential therapeutic target for these patients.
Mohammad Khurram Khan, Tahseen Nasti, Troy Kleber, et al.
The study authors conclude that concurrent pembrolizumab (Anti-PD-1) and SRS are safe and effective. They show, that early activation of CD8+PD1+Ki67+ T cells correlates with improved outcome. Clinical trial information: NCT02858869
Philip Wong, Marie Florescu, Marc-Emile Plourde, et al.
The study authors suggest - based on neurocognitive and quality of life assessments - that upfront radiosurgery during nivolumab is well-tolerated. High intracranial control was observed. However, deaths from extracranial disease progression resulted in short intracranial progression-free survival. Clinical trial information: 02978404.
Scott Randall Plotkin, Priya Kumthekar, Patrick Y. Wen, et al.
The study authors show that vistusertib treatment was associated with a progression-free survival rate at 6 months that exceeds the Response Assessment in Neuro-Oncology target of 35% for recurrent high-grade meningioma. Adverse events were tolerable in this patient population. According to the study authors, these data support the initiation of larger randomized studies of vistusertib in this setting. Clinical trial information: NCT03071874